An experimental small molecule helped restore the removal of mitochondria from dopamine-producing neurons in the brain. The findings may help in the development of new therapies for Parkinson's disease.
Clioquinol, an anti-parasitic medication, overcomes the effect of mutations in the LRRK2 gene associated with Parkinson's disease by restoring the acidity of lysosomes and clearing out protein aggregates.
Vitamin B12 significantly prevents the neurotoxicity of LRRK2 genetic variants associated with hereditary Parkinson's disease. The findings may help with the development of new therapies to combat the neurodegenerative disease.
A new study reveals a defective version of astrocytes may be linked to the build up of alpha synuclein and could spur Parkinson's disease. The findings show the important role glial cells play in Parkinson's and offers insights into new targets for therapies to fight the neurodegenerative disease.
Mutations in LRRK2 leads to dysfunctional auxilin and impaired synaptic vesicle endocytosis in Parkinson's patients, researchers report.
Studying what the LRRK2 gene does in macrophages infected with the bacterium that causes tuberculosis, researchers believe they may have identified a cause of Parkinson's disease.
A new study reveals the LRRK2 genetic mutation may alter cells circulating outside of the brain. Researchers report the mutation may alter how immune cells react to common illnesses, causing an inflammatory reaction in the brain that can lead to the development of Parkinson's disease.
A new study reveals LRRK is essential for the survival of dopamine neurons in the brain. The finding may prompt new treatments for Parkinson's disease.
Activating Nrf2 helps with the removal of LRRK2 and alpha synuclein, researchers report.